Cached score snapshot
US.RVTY · Revvity
110分制 61.5/110;5D動能v2 4/50;排序分 65.5/160
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling DOE best | +1.19% | -0.90% / +2.74% | 61.3% | 5% | Actual -2.18% · vs median -3.37% · inside 25-75 band |
| 30D observation | +10.07% | -1.44% / +21.85% | 68.8% | 13.8% | Actual outcome pending · 1 / 30 bars observed |
| Historical projection 10D n=160 | +0.74% | -0.84% / +2.47% | 60.6% | 5% | Actual outcome pending · 1 / 10 bars observed |
歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。
2026-06-12 → 2026-10-20 · 119 archived points · 2 Improving turn signal · 7 Deteriorating signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 20.6 · 資金流 13.2 · 5D動能v2 4
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Market inputs
Metrics snapshot
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
基本面 — 2.4/5 · 較差
Sub-items
資金流 — 13.2/20 · 一般
Sub-items
institutional
details
warning
市場環境 — 11/15 · 良好
Sub-items
vix
details
trend
details
qqq
spy
催化劑 — 2/20 · 較差
Sub-items
catalyst
details
風險管理 — 6.3/10 · 一般
Sub-items
position
details
stopLevels
strength_details
diversification
details
技術信號 — 20.6/30 · 一般
Sub-items
vcpPayload
vcp_metrics
情緒分析 — 6/10 · 一般
Sub-items
sentiment
details
sentimentData
Dimension contribution
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
Risk management
position
details
stopLevels
strength_details
diversification
details
Calculation audit log
基本面分析總分: 2.4/5分 資金流分析總分: 13.2/20分 市場環境分析總分: 11/15分 催化劑分析: 2/20分 風險管理總分: 6.3/10分 技術信號分析總分: 20.6/30分 情緒分析: 6/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
atr
cci
cmf
kdj
mfi
obv
rsi
sar
ma50
macd
vwap
volume
derived
ma_cross
bollinger
rsi_short
macd_short
volume_ratio
Raw calculation JSON
{
"risk": {
"level": "Elevated",
"reason": "risk management score >= 5/10",
"position": {
"score": 1.1,
"details": {
"atrPct": 3.2994176377176956,
"turnoverUsdM": 189.482128662092,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RVTY",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 118.6942,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 0.5,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 6.6,
"take_profit_price": 133.7886,
"target_multiplier": 1.6,
"technical_strength": 1.5,
"take_profit_percent": 5.3
},
"positionPoints": 1.1,
"stopLossPoints": 1.8,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 6.598835275435391,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 65.5,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 61.5,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 4
},
"market": {
"ma20": 123.6515,
"ma50": 116.6782,
"close": 127.08,
"prevClose": 130.22,
"avgVolume20": 1553342,
"volumeRatio": 0.96,
"changePercent": -2.41
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 4,
"details": {
"ret_5d": -0.012357177275200026,
"max_score": 50,
"max_total": 50,
"raw_total": 4,
"vcp_bonus": 0,
"vol_ratio": 0.9672820925344474,
"ret_points": 0,
"vol_points": 0,
"range_ratio": 0.7313196523165912,
"volat_points": 0,
"day_range_pct": 0.02085292696171022,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 0,
"partial_history": false,
"pullback_points": 4,
"breakout_vol_bonus": 0,
"first_breakout_20d": false,
"return_window_days": 5,
"first_breakout_bonus": 0,
"breakout_quality_points": 0
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 65.5,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 2.4,
"label": "基本面",
"weight": "5/110",
"normalized": 48,
"contribution": 2.4
},
{
"raw": 13.2,
"label": "資金流",
"weight": "20/110",
"normalized": 66,
"contribution": 13.2
},
{
"raw": 11,
"label": "市場環境",
"weight": "15/110",
"normalized": 73.33,
"contribution": 11
},
{
"raw": 2,
"label": "催化劑",
"weight": "20/110",
"normalized": 10,
"contribution": 2
},
{
"raw": 6.3,
"label": "風險管理",
"weight": "10/110",
"normalized": 63,
"contribution": 6.3
},
{
"raw": 20.6,
"label": "技術信號",
"weight": "30/110",
"normalized": 68.67,
"contribution": 20.6
},
{
"raw": 6,
"label": "情緒分析",
"weight": "10/110",
"normalized": 60,
"contribution": 6
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "checked",
"standard110": {
"rating": "觀望",
"result": 61.5,
"details": [
"基本面分析總分: 2.4/5分",
"資金流分析總分: 13.2/20分",
"市場環境分析總分: 11/15分",
"催化劑分析: 2/20分",
"風險管理總分: 6.3/10分",
"技術信號分析總分: 20.6/30分",
"情緒分析: 6/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 2,
"基本面": 2.4,
"資金流": 13.2,
"市場環境": 11,
"情緒分析": 6,
"技術信號": 20.6,
"風險管理": 6.3
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 2,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 5,
"catalystCount": 0
}
},
"catalystPoints": 2
}
},
"基本面": {
"max": 5,
"grade": "較差",
"items": {
"pbPoints": 0.5,
"pePoints": 0.2,
"epsPoints": 0,
"roePoints": 0,
"debtPoints": 0.5,
"marginPoints": 0,
"turnoverUsdM": 189.482128662092,
"volumePoints": 0.5,
"revenuePoints": 0,
"dividendPoints": 0.3,
"marketCapPoints": 0.4
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "一般",
"items": {
"cmfPoints": 3.2,
"mfiPoints": 3.2,
"obvPoints": 0.8,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.RVTY",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "良好",
"items": {
"vix": {
"score": 2.4,
"details": {
"source": "twelvedata+fred",
"vixClose": 15.3
}
},
"trend": {
"score": 3.4,
"details": {
"qqq": {
"ma20": 717.3850005500001,
"ma50": 711.3217994399997,
"name": "QQQ",
"close": 718.35999,
"points": 2
},
"spy": {
"ma20": 768.6994929500001,
"ma50": 757.5966012200001,
"name": "SPY",
"close": 765.96002,
"points": 1.4
},
"source": "twelvedata+fred"
}
},
"atrPct": 3.2994176377176956,
"atrPoints": 2,
"cciPoints": 3.2,
"vixPoints": 2.4,
"marketTrendPoints": 3.4
}
},
"情緒分析": {
"max": 10,
"grade": "一般",
"items": {
"sentiment": {
"score": 6,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 5,
"negativeHits": 0,
"positiveHits": 3,
"sentimentScoreRaw": 1.4
}
},
"sentimentData": {
"raw": [
{
"id": 141394957,
"url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
"category": "company",
"datetime": 1788401656,
"headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
},
{
"id": 141376585,
"url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
"category": "company",
"datetime": 1788350787,
"headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
},
{
"id": 141374543,
"url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
"image": "",
"source": "Fintel",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1788331013,
"headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
},
{
"id": 141370258,
"url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
"category": "company",
"datetime": 1788282002,
"headline": "What Makes Revvity (RVTY) a New Buy Stock"
},
{
"id": 141202718,
"url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
"category": "company",
"datetime": 1786468489,
"headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
}
],
"raw_source": [
{
"id": 141950366,
"url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
"category": "company",
"datetime": 1788878940,
"headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
},
{
"id": 141425678,
"url": "https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.",
"category": "company",
"datetime": 1788526140,
"headline": "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"
},
{
"id": 141420277,
"url": "https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher",
"category": "company",
"datetime": 1788518880,
"headline": "Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share"
},
{
"id": 141449917,
"url": "https://finnhub.io/api/news?id=2f5b6dbf3c6e63d29e248fc2bc5f667c787cd9f592de5860faa835e287e2cc01",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.",
"category": "company",
"datetime": 1788513490,
"headline": "Keybanc Maintains Overweight on Revvity, Raises Price Target to $165"
},
{
"id": 141394957,
"url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
"category": "company",
"datetime": 1788401656,
"headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
},
{
"id": 141376585,
"url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
"category": "company",
"datetime": 1788350787,
"headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
},
{
"id": 141374543,
"url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
"image": "",
"source": "Fintel",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1788331013,
"headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
},
{
"id": 141373643,
"url": "https://finnhub.io/api/news?id=586a7b0273e63c068b81acc8775f2c6ac9290074de64940276220f0e54d8f76b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
"category": "company",
"datetime": 1788294620,
"headline": "3 Hyped Up Stocks We Find Risky"
},
{
"id": 141370258,
"url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
"category": "company",
"datetime": 1788282002,
"headline": "What Makes Revvity (RVTY) a New Buy Stock"
},
{
"id": 141370259,
"url": "https://finnhub.io/api/news?id=b4010c5290b28cfc54157cb45359ef75b9687f7cc7d4fb5bcd195348a5cc80a2",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo",
"category": "company",
"datetime": 1788280978,
"headline": "Revvity Faces Growth Challenges Amid Rising Competition, RBC Says"
},
{
"id": 141370883,
"url": "https://finnhub.io/api/news?id=da5596eb573a2739f70a4762282fc12f50cb2181b295291669cc4c0452c29761",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.",
"category": "company",
"datetime": 1788249814,
"headline": "RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135"
},
{
"id": 141361171,
"url": "https://finnhub.io/api/news?id=40e9f3152f995605f71edc54cd5e8da04b68760f2b599ba43b23754aa3a6049b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.",
"category": "company",
"datetime": 1788072487,
"headline": "How Is UnitedHealth Group's Stock Performance Compared to Other Healthcare Plan Stocks?"
},
{
"id": 141365522,
"url": "https://finnhub.io/api/news?id=ee488ce9869916a3010f25f71ecd7d44f2eb7e982a65bdbcd691644f069d6b25",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Investors need to pay close attention to RVTY stock based on the movements in the options market lately.",
"category": "company",
"datetime": 1787589000,
"headline": "Is the Options Market Predicting a Spike in Revvity Stock?"
},
{
"id": 141365523,
"url": "https://finnhub.io/api/news?id=eb1cf6f63665ff456ed353f202bb56f9038280ac16ecae9524ce05ca57689b3e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
"category": "company",
"datetime": 1787585403,
"headline": "Revvity Stock: Is Wall Street Bullish or Bearish?"
},
{
"id": 141263724,
"url": "https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
"category": "company",
"datetime": 1787252701,
"headline": "Exploring the top movers within the S&P500 index during today's session."
},
{
"id": 141230562,
"url": "https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a",
"image": "",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1786857318,
"headline": "Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"
},
{
"id": 141218677,
"url": "https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df",
"image": "",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1786721166,
"headline": "Danaher: 2027 Growth Reacceleration Should Drive Upside"
},
{
"id": 141206709,
"url": "https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.",
"category": "company",
"datetime": 1786629600,
"headline": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"
},
{
"id": 141202717,
"url": "https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen",
"category": "company",
"datetime": 1786587660,
"headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"
},
{
"id": 141202718,
"url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
"category": "company",
"datetime": 1786468489,
"headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
},
{
"id": 141202719,
"url": "https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:",
"category": "company",
"datetime": 1786449600,
"headline": "Revvity to Present at Upcoming Investor Conferences"
},
{
"id": 141174464,
"url": "https://finnhub.io/api/news?id=63dd3feb8ba49e1ae84ce6a141b45b7a3b89f86583deb193b3dea0bea2fb5247",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.",
"category": "company",
"datetime": 1786363200,
"headline": "Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing"
},
{
"id": 141173746,
"url": "https://finnhub.io/api/news?id=40b71ceb7b13d365c949f86e7e49081f3457d6ee7e752ab19caba47ee97b41d8",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
"category": "company",
"datetime": 1786360642,
"headline": "1 Profitable Stock on Our Buy List and 2 We Find Risky"
},
{
"id": 141164551,
"url": "https://finnhub.io/api/news?id=28240c7696bd84e8c1650ca65c32607de843b27341b0f3371fb567d0795f9fd1",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows",
"category": "company",
"datetime": 1786248230,
"headline": "Revvity Q2 Earnings Call Highlights"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 5,
"negative_hits": 0,
"positive_hits": 3,
"recomputed_at_score": true,
"sentiment_score_raw": 1.4,
"source_article_count": 24,
"discarded_article_count": 19
},
"sentimentPoints": 6
}
},
"技術信號": {
"max": 30,
"raw": 20.6,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 1.2000000000000002,
"vcpPoints": 2.7,
"macdPoints": 4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 2.7,
"vcp_reason": "波幅收縮(20.1%→9.1%);跌縮量(近10日3日);站上MA50;升放量(近10日2日);Ready=Y;Confirm=N",
"vcp_metrics": {
"up_days": 4,
"vol_ref": 1638203.3333333333,
"down_days": 5,
"vcp_ready": true,
"above_ma50": true,
"avg_vol_10": 1698800,
"avg_vol_20": 1541480,
"avg_vol_30": 1638203.3333333333,
"range_pct_10": 0.09143846252064117,
"range_pct_20": 0.1598992735300712,
"range_pct_30": 0.20081837896099497,
"up_expand_ok": true,
"lookback_used": 59,
"near_20d_high": true,
"contraction_ok": true,
"down_shrink_ok": true,
"up_expand_days": 2,
"breakout_20d_ok": false,
"vol_ratio_10_30": 1.0369897102720258,
"dist_to_20d_high": 0.04451126315789479,
"down_shrink_days": 3,
"breakout_level_20d": 133,
"vcp_breakout_confirm": false,
"contraction_ratio_10_30": 0.45532915360501586
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": true
},
"kdjAdxPoints": 0.5,
"rsiKdjPoints": 2.4,
"volumeWeight": 2,
"maCrossPoints": 1.6,
"shortRsiPoints": 0.4,
"shortMacdPoints": 0.4,
"volConfirmPoints": 0.6,
"volumePointsTechnical": 0.8
}
},
"風險管理": {
"max": 10,
"grade": "一般",
"items": {
"position": {
"score": 1.1,
"details": {
"atrPct": 3.2994176377176956,
"turnoverUsdM": 189.482128662092,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RVTY",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 118.6942,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 0.5,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 6.6,
"take_profit_price": 133.7886,
"target_multiplier": 1.6,
"technical_strength": 1.5,
"take_profit_percent": 5.3
},
"positionPoints": 1.1,
"stopLossPoints": 1.8,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 6.598835275435391,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": true,
"missingFields": [],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 85.71,
"atr": {
"atr": 4.1929,
"rule": "ATR / current price; lower volatility scores higher",
"score": 4,
"atr_pct": 3.3
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "適中偏強",
"score": 8,
"value": 64.28
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "資金流入",
"score": 8,
"value": 0.2946
},
"kdj": {
"d": 79.59,
"j": 43.34,
"k": 67.5,
"rule": "Cursor_18.24 K/D cross",
"score": 0,
"signal": "死叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "入貨中",
"score": 8,
"value": 68.98
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 2,
"trend": "資金流出",
"value": 10418854,
"recentSlope": -555804.6,
"previousSlope": 336160
},
"rsi": 71.65,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 4,
"trend": "下降",
"value": 133,
"position": "SAR喺價上",
"distancePct": 4.66,
"previousTrend": "上升"
},
"ma50": 116.6782,
"macd": {
"macd": 4.209307111240491,
"trend": "強烈看漲",
"signal": 4.107223083560831,
"histogram": 0.10208402767965996
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 124.1891,
"position": "連續5日>VWAP",
"consecutiveAbove": 24
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "無力",
"ratio": 0.96,
"score": 4,
"avgVolume": 1553342,
"currentVolume": 1491046
},
"derived": {
"ma20": 123.6515,
"ma50": 116.6782,
"prevClose": 130.22,
"avgVolume10": 1697365,
"avgVolume20": 1553342,
"changePercent": -2.41,
"avgVolumeForScore": 1553342
},
"ma_cross": {
"ma20": 123.6515,
"ma50": 116.6782,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "多頭",
"score": 4,
"prevMa20": 123.0985,
"prevMa50": 116.397,
"spreadPct": 5.98,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 112.5495,
"upper": 134.7535,
"position": "上半部"
},
"rsi_short": 41.75,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 0.96
}
}
}
Raw metrics JSON
{
"close": 127.08,
"volume": 1491046,
"changePercent": -2.41
}
Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.